# 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

> **NCT03831711** · PHASE1,PHASE2 · COMPLETED · sponsor: **Andrei Iagaru** · enrollment: 5 (actual)

## Conditions studied

- Breast Carcinoma
- Estrogen Receptor Positive

## Interventions

- **DRUG:** Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **DEVICE:** Investigational software and coils in PET/MR scan

## Key facts

- **NCT ID:** NCT03831711
- **Lead sponsor:** Andrei Iagaru
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-11-15
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2023-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03831711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03831711, "68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03831711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*